Iksuda Therapeutics
- Biotech or pharma, therapeutic R&D
Iksuda Therapeutics is a clinical-stage ADC development company focused on advancing class-leading ADCs for hard-to-treat tumors. We have designed, developed and preclinically validated a novel protein alkylating payload, 'ProAlk', which we now incorporate into our early-stage ADC programs.
Iksuda designs and develops ADCs based on tumor-selective payload release & activation and have built a portfolio of ADC-relevant platforms, including proprietary bioconjugation chemistries, linker formats and payloads. Our ProAlk payload is the first of its kind in the ADC arena and has potential significance in meeting the recognized challenge of ADC sequencing, especially given the vast array of topoisomerase I inhibitor- and tubulin binder-based ADCs in preclinical & clinical development.
We are seeking license and collaboration partners for our ADC programs and asset platforms.
Address
Newcastle-Upon-TyneTyne and Wear
United Kingdom
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}